SR One reinvested in a series B round for the degenerative disorder drug developer that was led by venture fund Logos Capital.

GV and Novartis Venture Fund joined 6 Dimensions Capital in a round that brought Harvard’s oncology drug developer's overall funding to $160m.

Johnson & Johnson Innovation – JJDC has co-led the computational pathology technology provider's series C round to take its total funding to $195m.

Atalanta Therapeutics has launched out of UMass with $110m in combined series A and partnership funding to develop therapies for neurodegenerative diseases.

IP Group portfolio company Hinge Health has pushed its valuation to $3bn following a $300m series D round co-led by Coatue Management and Tiger Global.

Investors have thrown their backing behind a round topping $100m for Stanford-linked production automation robot developer Flexiv.

The intelligent chipmaker, which traces its roots back to University of Bristol, has secured series E funding at a $2.77bn valuation.

Based on inventions from Harvard and Dana-Farber Cancer Institute, Neomorph was launched earlier this year with the support of Deerfield Management.

Fudan University’s Furong Investment has co-led a round for Singlera Genomics, which will use the cash to advance its pipeline of cancer screening products.

The challenger bank’s Vanderbilt University-backed series G has been boosted by new funding at the same $1.57bn valuation.